FR22C1051I2 - Melanges d'analogues de cyclosporine et leur utilisation comme agents immunomodulateurs - Google Patents

Melanges d'analogues de cyclosporine et leur utilisation comme agents immunomodulateurs

Info

Publication number
FR22C1051I2
FR22C1051I2 FR22C1051C FR22C1051C FR22C1051I2 FR 22C1051 I2 FR22C1051 I2 FR 22C1051I2 FR 22C1051 C FR22C1051 C FR 22C1051C FR 22C1051 C FR22C1051 C FR 22C1051C FR 22C1051 I2 FR22C1051 I2 FR 22C1051I2
Authority
FR
France
Prior art keywords
mixtures
immunomodulating agents
cyclosporine analogs
cyclosporine
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1051C
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR22C1051I1 publication Critical patent/FR22C1051I1/fr
Application granted granted Critical
Publication of FR22C1051I2 publication Critical patent/FR22C1051I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
FR22C1051C 2001-10-19 2022-10-14 Melanges d'analogues de cyclosporine et leur utilisation comme agents immunomodulateurs Active FR22C1051I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19
PCT/CA2002/001560 WO2003033527A2 (en) 2001-10-19 2002-10-17 Cyclosporine analogue mixtures and their use as immunomodulating agents

Publications (2)

Publication Number Publication Date
FR22C1051I1 FR22C1051I1 (fr) 2022-12-16
FR22C1051I2 true FR22C1051I2 (fr) 2023-11-17

Family

ID=23358378

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1051C Active FR22C1051I2 (fr) 2001-10-19 2022-10-14 Melanges d'analogues de cyclosporine et leur utilisation comme agents immunomodulateurs

Country Status (38)

Country Link
US (2) US20110092669A1 (enExample)
EP (2) EP1816138A1 (enExample)
JP (4) JP2005511538A (enExample)
KR (1) KR100992850B1 (enExample)
CN (1) CN100344648C (enExample)
AR (1) AR036853A1 (enExample)
AT (1) ATE401339T1 (enExample)
AU (1) AU2002331510B2 (enExample)
BE (1) BE2022C547I2 (enExample)
BR (1) BR0213659A (enExample)
CA (2) CA2727642C (enExample)
CO (1) CO5570682A2 (enExample)
CY (2) CY1108410T1 (enExample)
DE (1) DE60227686D1 (enExample)
DK (1) DK1436322T3 (enExample)
EC (3) ECSP045059A (enExample)
ES (1) ES2310604T3 (enExample)
FI (1) FIC20220041I1 (enExample)
FR (1) FR22C1051I2 (enExample)
HR (1) HRP20040353B1 (enExample)
IL (2) IL160762A0 (enExample)
LT (1) LTC1436322I2 (enExample)
MA (1) MA26337A1 (enExample)
ME (1) ME00487B (enExample)
MX (1) MXPA04003624A (enExample)
MY (1) MY187182A (enExample)
NL (1) NL301200I2 (enExample)
NO (2) NO331745B1 (enExample)
NZ (1) NZ531945A (enExample)
PL (1) PL210697B1 (enExample)
PT (1) PT1436322E (enExample)
PY (2) PY0225477A (enExample)
RU (1) RU2337106C2 (enExample)
SI (1) SI1436322T1 (enExample)
TN (1) TNSN04069A1 (enExample)
UY (1) UY27502A1 (enExample)
WO (1) WO2003033527A2 (enExample)
ZA (1) ZA200402270B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100344648C (zh) * 2001-10-19 2007-10-24 伊索泰克尼卡股份有限公司 环孢菌素类似物混合物及其在制备免疫调节剂中的用途
MXPA04003625A (es) 2001-10-19 2004-12-02 Sotechnika Inc Sintesis de analogos de ciclosporina.
US7538084B2 (en) 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
JP2008515886A (ja) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
WO2006063470A1 (en) * 2004-12-17 2006-06-22 Isotechnika Inc. Metabolites of cyclosporin analogs
PT1957518E (pt) * 2005-10-26 2016-02-26 Astellas Pharma Inc Novos compostos peptídicos cíclicos
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
KR20100017547A (ko) * 2007-05-02 2010-02-16 아스텔라스세이야쿠 가부시키가이샤 신규 시클릭 펩티드 화합물
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
RU2361604C1 (ru) * 2007-10-29 2009-07-20 Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий) Способ лечения атопического дерматита
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
BR112013014890B1 (pt) 2010-12-15 2023-10-24 Contravir Pharmaceuticals, Inc Composto análogo de moléculas pertencentes à família ciclosporina, composição farmacêutica compreendendo o mesmo, uso terapêutico ou profilático do referido composto e processos para a preparação dos mesmos
GB201222455D0 (en) 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
WO2018102565A1 (en) * 2016-11-30 2018-06-07 Schrödinger, Inc. Graphical user interface for chemical transition state calculations
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
JP2020513280A (ja) 2016-12-14 2020-05-14 プロジェニティ， インコーポレイテッド 消化管疾病の免疫抑制剤による治療
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US10286036B2 (en) * 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
IL296586B1 (en) * 2020-03-26 2026-04-01 Farsight Medical Tech Shanghai Co Ltd Cyclophilin inhibitors and their uses
EP4201952A1 (en) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Process for the controlled synthesis of voclosporin
EP4584279A1 (en) * 2022-09-09 2025-07-16 Dr. Reddy's Laboratories Limited Improved process for the preparation of voclosporin
IT202300001116A1 (it) * 2023-01-25 2024-07-25 Indena Spa Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
IT202300001056A1 (it) * 2023-01-25 2024-07-25 Procos Spa Nuovo processo per la preparazione di voclosporina amorfa
WO2025119925A1 (en) 2023-12-05 2025-06-12 Medichem, S.A. Process for preparing voclosporin
IT202300028041A1 (it) * 2023-12-27 2025-06-27 Indena Spa Processo per la preparazione di voclosporina

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278545A (en) * 1979-09-12 1981-07-14 The Bendix Corporation Apparatus for separating solids and liquid components
CH670644A5 (enExample) * 1986-12-18 1989-06-30 Lonza Ag
US5162540A (en) * 1986-12-18 1992-11-10 Lonza Ltd. Process for the production of (+) biotin
DE3884470T2 (de) * 1987-06-17 1994-03-10 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel.
US5972630A (en) * 1991-08-19 1999-10-26 Dade Behring Marburg Gmbh Homogeneous immunoassays using enzyme inhibitors
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
ATE392891T1 (de) * 1996-06-19 2008-05-15 Novartis Pharma Gmbh Cyclosporin enthaltende präparate
US5939406A (en) * 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
AU750245B2 (en) * 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
MXPA04003625A (es) * 2001-10-19 2004-12-02 Sotechnika Inc Sintesis de analogos de ciclosporina.
CN100344648C (zh) * 2001-10-19 2007-10-24 伊索泰克尼卡股份有限公司 环孢菌素类似物混合物及其在制备免疫调节剂中的用途

Also Published As

Publication number Publication date
CA2727642C (en) 2014-02-04
NZ531945A (en) 2006-01-27
JP5272140B2 (ja) 2013-08-28
NO2022042I1 (no) 2022-10-14
NL301200I2 (nl) 2024-07-25
CO5570682A2 (es) 2005-10-31
ECSP045061A (es) 2004-08-27
DE60227686D1 (de) 2008-08-28
AU2002331510B2 (en) 2008-05-01
LTC1436322I2 (enExample) 2023-06-26
HRP20040353A2 (en) 2005-04-30
UY27502A1 (es) 2003-04-30
AR036853A1 (es) 2004-10-06
KR20050037421A (ko) 2005-04-21
LTPA2022521I1 (enExample) 2022-11-10
JP2009197036A (ja) 2009-09-03
ME00487B (me) 2011-10-10
PY0225477A (es) 2004-05-03
US20110092669A1 (en) 2011-04-21
DK1436322T3 (da) 2008-11-03
NO20042029L (no) 2004-05-14
ECSP045060A (es) 2004-07-23
SI1436322T1 (sl) 2008-12-31
CN1571794A (zh) 2005-01-26
JP2011006417A (ja) 2011-01-13
IL160762A (en) 2010-11-30
CY1108410T1 (el) 2012-05-23
ES2310604T3 (es) 2009-01-16
CY2022030I1 (el) 2023-01-27
BE2022C547I2 (enExample) 2022-10-19
HRP20040353B1 (hr) 2012-10-31
KR100992850B1 (ko) 2010-11-09
PY0225478A (es) 2004-05-03
CA2460685C (en) 2014-05-27
JP2013136597A (ja) 2013-07-11
HK1062567A1 (en) 2004-11-12
PL210697B1 (pl) 2012-02-29
CY2022030I2 (el) 2023-06-09
PL370501A1 (en) 2005-05-30
WO2003033527A3 (en) 2003-10-16
NO331745B1 (no) 2012-03-19
EP1436322A2 (en) 2004-07-14
ECSP045059A (es) 2004-07-23
EP1436322B1 (en) 2008-07-16
BR0213659A (pt) 2004-10-26
CN100344648C (zh) 2007-10-24
MXPA04003624A (es) 2004-12-06
US20140288266A1 (en) 2014-09-25
CA2727642A1 (en) 2003-04-24
RU2004110941A (ru) 2005-08-10
JP2005511538A (ja) 2005-04-28
WO2003033527A2 (en) 2003-04-24
CA2460685A1 (en) 2003-04-24
RU2337106C2 (ru) 2008-10-27
FR22C1051I1 (fr) 2022-12-16
MA26337A1 (fr) 2004-10-01
PT1436322E (pt) 2008-10-23
MY187182A (en) 2021-09-08
IL160762A0 (en) 2004-08-31
FIC20220041I1 (fi) 2022-10-14
ATE401339T1 (de) 2008-08-15
EP1816138A1 (en) 2007-08-08
TNSN04069A1 (en) 2006-06-01
ZA200402270B (en) 2005-05-25

Similar Documents

Publication Publication Date Title
FR22C1051I2 (fr) Melanges d'analogues de cyclosporine et leur utilisation comme agents immunomodulateurs
EP1319762A4 (en) DRIVER'S HOUSE FOR EARTH-MOVING MACHINE
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
EP1551436A4 (en) FORMULATIONS FOR AMYLIN AGONIST PEPTIDES
FR2765801B1 (fr) Utilisation de monoesters d'arbutine comme agent depigmentant
DE69811436D1 (de) Verbesserte Verarbeitbarkeit von Silica-gefüllten Kautschukzusammensetzungen
IS2325B (is) Örgerðar samsetningar epleróns
PT996430E (pt) Composicoes de analogos nucleotidicos
DE59910836D1 (de) Dermal applizierbare wasserhaltige formulierungen von parasitiziden
EP1278567A4 (en) SPACER HOLDER ASSEMBLY FOR VENTILATION ACCESSORIES
IL160190A0 (en) Use of copolymer to produce a galenic form containining a peptide or a protein as active agent
ID25765A (id) Komposisi pembersih kulit
NO20025964L (no) Ny interferon for behandling av multippel sklerose
AU2517399A (en) Utilization of substituted sulfonamides as antiviral agents and novel substances
EP1169048A4 (en) Hyaluronic acid mimics and methods related thereto
HUP0004799A3 (en) Use of electrolyte mixtures as sequestering agents
FR2799755B1 (fr) Preparation de chlorure d'alcoylsufonyle perfluore en alpha du soufre
EE200000694A (et) Inimese rekombinantse iterferooni beeta-1a (IFN-ß-1a) formulatsioon
DE69930733D1 (de) Herstellung von substituierten (amino)alkoxysilanen
AR026890A1 (es) Composiciones de tenocitos, preparaciones y utilizaciones
EP1406921A4 (en) HYPOGLYCAEMIC PEPTIDES AND METHOD FOR USE THEREOF
EP1071754A4 (en) Recombinant secoisolariciresinol dehydrogenase, and methods of use
EP1230928A4 (en) USE OF PEPTIDE
ITMI20000810A0 (it) Procedimento per la preparazione di 5'-acetilstavudina
TW484436U (en) Improved structure of roque stick